申请人:Boehringer Mannheim GmbH
公开号:US05397794A1
公开(公告)日:1995-03-14
The present invention concerns the use of compounds of the general formula I ##STR1## for the preparation of medicaments for the treatment of viral or retroviral infections, whereby R signifies a hydrogen atom or a straight-chained or branched, saturated or unsaturated alkyl radical with 1-7 carbon atoms, which can possibly be substituted by phenyl, or a phenyl ring which can possibly be substituted one or more times by C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy, hydroxyl, trifluoromethyl, methylsulphonyl or halogen, such as fluorine, chlorine or bromine, n stands for the numbers 0, 1 or 2, as well as of their pharmacologically compatible salts or tautomers.
本发明涉及使用通式I的化合物 ##STR1## 用于制备用于治疗病毒或逆转录病毒感染的药物,其中R表示氢原子或具有1-7个碳原子的直链或支链、饱和或不饱和的烷基基团,可能被苯基取代,或者可能被C.sub.1-C.sub.4-烷基、C.sub.1-C.sub.4-烷氧基、羟基、三氟甲基、甲基磺酰基或卤素(如氟、氯或溴)取代的苯环,n代表数字0、1或2,以及它们的药理学兼容盐或互变异构体。